ZNTL · XBRL financial data

Zentalis Pharmaceuticals financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ZNTL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	0	0	67	0
Research and development	85	176	173	190	168	107
General and administrative	34	41	55	64	87	38
Total operating expenses	119	217	227	300	259	153
Operating income (loss)	(119)	(217)	(227)	(300)	(191)	(153)
Income tax expense (benefit)	0	(0)	(0)	(1)	0	0
Net income (loss)	(118)	(159)	(237)	(292)	(166)	(137)
Earnings per share, basic USD per share	(4.19)	(3.72)	(4.48)	(4.47)	(2.33)	(1.91)
Earnings per share, diluted USD per share	(4.19)	0.00	(4.48)	(4.47)	(2.33)	(1.91)
Weighted average shares, basic millions of shares	28	43	53	65	71	72
Weighted average shares, diluted millions of shares	28	43	53	65	71	72

Fiscal years (ZNTL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	55	60	43	28	34	36
Marketable securities	284	—	—	455	318	210
Accounts receivable	0	0	—	0	5	0
Prepaid and other current assets	6	11	15	14	10	7
Total current assets	345	351	452	497	386	253
Property and equipment, net	1	8	8	6	5	3
Right-of-use asset	3	45	42	36	33	26
Goodwill	4	4	4	4	0	—
Total assets	366	455	539	552	430	289
Accounts payable	9	12	11	15	7	7
Accrued liabilities	20	32	45	54	45	29
Total current liabilities	29	44	57	69	53	37
Lease liability, non-current	1	44	45	43	40	36
Total liabilities	32	90	105	114	93	73
Accumulated deficit	(201)	(360)	(596)	(889)	(1,054)	(1,191)
Total stockholders' equity	309	364	434	437	337	216
Total liabilities and equity	366	455	539	552	430	289
Common shares outstanding (cover page) millions of shares	41	46	59	71	72	71

Fiscal years (ZNTL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(118)	(159)	(237)	(292)	(166)	(137)
Stock-based compensation	23	36	47	55	67	21
Depreciation and amortization	0	1	1	1	1	1
Net cash from operating activities	(87)	(154)	(164)	(208)	(171)	(125)
Purchases of property and equipment	1	6	3	1	0	0
Net cash from investing activities	(285)	(18)	(114)	(44)	177	132
Proceeds from issuing common stock	155	172	258	236	0	5
Share repurchases	—	—	—	0	0	10
Net cash from financing activities	360	179	261	237	0	(4)
Net change in cash	(11)	6	(17)	(15)	6	2

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Zentalis Pharmaceuticals	25	not reported	(37)*	71.7M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23	not reported	(30)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85	0	(15)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Veru	24	not reported	(5.5)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Lifevantage	15	42*	4.8*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Medicinova	25	0.5	(1.9)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	18	0.6	(10)*	10.2M	1.1 quarters	Q3 FY26 10-QSep 30, 2026
Oncolytics Biotech	4.1	not reported	(8.1)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	42	33	(4)*	115.3M	9.1 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 7, 2026, 2:37 PM ET. The filing on SEC.gov is the record.